Novartis Announces Leadership Transition in Innovative Medicines Division

On September 6, Novartis announced that Marie-France Tschudin, the current President of International Innovative Medicines and Chief Commercial Officer, will step down from her position. She will also step down from the Novartis Executive Committee (ECN), effective September 15. Prior to this, Tschudin had been responsible for nearly 7 years of commercial leadership at Novartis.

Patrick Horber, currently Senior Vice President and President of Immunology at AbbVie, will assume the position from Tschudin later this year, while also joining the Novartis Executive Committee (ECN), reporting directly to Dr. Vas Narasimhan, CEO of Novartis. During the transition period between Tschudin's departure and Horber's appointment, Mukul Mehta, Chief Financial Officer of International Operations, will temporarily lead the division.

Marie-France Tschudin (Source: Novartis official website)

Previously, Novartis underwent a series of restructuring plans, including layoffs, establishing a new organizational structure, and spinning off its generic drug subsidiary, Sandoz. Vas Narasimhan, CEO of Novartis, aims to reshape Novartis into a "pure" company focused on producing innovative medicines.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message to the WeChat Official Account's backend or send a message, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.